Backgroud& Aims:Interleukin-22(IL-22) is up-regulated in liver tissues of patients with hepatitis C virus(HCV) and demonstrates anti-fibrotic functions in mouse ***,the role of IL-22 in HCV-associatedliver fib...
详细信息
Backgroud& Aims:Interleukin-22(IL-22) is up-regulated in liver tissues of patients with hepatitis C virus(HCV) and demonstrates anti-fibrotic functions in mouse ***,the role of IL-22 in HCV-associatedliver fibrosis is poorly *** study is aimed to investigate the role of IL-22 in patients with HCV infection and the possible ***:The levels of IL-22 in plasma and frequencies of peripheral IL-22-producing cells were analyzed in acohort of HCV-infected patients including 32 with chronic hepatitis C(CHC),64withHCV-associated liver cirrhosis(LC),and 30 healthy subjects as *** distribution ofIL-22 cells in situ in liver tissues was observed by ***-22 receptor expressionwas studied on liver biopsies and in human hepatic stellatecells as well as their response to recombinant IL-22 by flowcytometry and ***:Patients with CHC and especially LC disclosed significant increases inperipheral numbers of IL-22-producing cells as well as in IL-22 *** increased intrahepatic IL-22 cells were positively correlatedwith fibrotic staging scores and clinical progressionfrom CHC to ***,the majority of IL-22 cellswere located in fibrotic areas in the liver of patients withcirrhosisand co-localized witha-smooth muscle actin(a-SMA) positive hepatic stellate cells(HSCs).In vitro,administration of IL-22 was accompanied with increased expression ofα-SMA,inhibitedLX-2 cells apoptosis,and up-regulated collagen production by LX-2 ***:IL-22 may contribute to the fibrogenesis of HCV-associated liver fibrosis by activating the hepatic stellate *** findings appear to be relevant to the development of of novel therapies targeting IL-22/IL-22R1 for patients with HCV infection.
Backgroud&Aims:Non-alcoholic steatoheaptitis(NASH),the critical stage of non-alcoholic fatty liver disease(NAFLD),is of chronic progression and can develop cirrhosis and even hepatocellular carcinoma(HCC).Seeking ...
详细信息
Backgroud&Aims:Non-alcoholic steatoheaptitis(NASH),the critical stage of non-alcoholic fatty liver disease(NAFLD),is of chronic progression and can develop cirrhosis and even hepatocellular carcinoma(HCC).Seeking non-invasive biomarkers in diagnosing NASH is a worldwide heated *** study aims at testing the accuracy of the combination of cytokeratin-18 M30 fragment(CK-18-M30),fibroblast growth factor 21(FGF-21),interleukin 1 receptor antagonist(IL-1Ra),pigment epithelium-derived factor(PEDF) and osteoprotegerin(OPG) in diagnosing NAFLD and ***:A large-cohort prospective study was conducted on 242 patients with biopsy-proven NAFLD,randomly divided into NAFLD training group(n=179) and validation group(n=63),and 91 ageand gender-matched healthy subjects as *** biomarker levels were measured by enzyme-linked immunosorbent ***:Serum levels of CK-18-M30,FGF-21,IL-IRa and PEDF increased,while OPG decreased in a stepwise fashion in controls,non-NASH NAFLD patients and NASH patients(P <.01).Thearea under receiver-operating characteristics curve(AUROC)to diagnose NASH was 0.86 for CK-18-M30,0.89 for FGF-21,0.89 for IL-IRa,0.89 for PEDF and 0.89 for *** cut-offs of203 U/L,CK-18-M30 had 71%negative predictive value(NPV) and 77%positive predictive value(PPV) to diagnose NASH.A 5-step approach measuring CK-18-M30 followed by FGF21,IL-IRa,PEDF and OPG gradually improved the NPV to 76%and PPV to 85%,which reached80%and 76%> respectively in validation ***:Stepwise combination of CK-18-M30,FGF-21,IL-IRa,PEDF and OPG can greatly improve the accuracy in diagnosing NASH compared to single biomarker,which is worth clinical application.
暂无评论